
Electroceuticals/Bioelectric Medicine Market by Product (Cardiac Pacemakers & Implantable Cardioverter Defibrillators, Cochlear Implants, Deep Brain Stimulators), Device (Implantable Electroceutical Devices, Noninvasive Electroceutical Devices), Applicati
Description
Electroceuticals/Bioelectric Medicine Market by Product (Cardiac Pacemakers & Implantable Cardioverter Defibrillators, Cochlear Implants, Deep Brain Stimulators), Device (Implantable Electroceutical Devices, Noninvasive Electroceutical Devices), Applicati
The Electroceuticals/Bioelectric Medicine Market size was estimated at USD 25.06 billion in 2023 and expected to reach USD 27.05 billion in 2024, at a CAGR 8.11% to reach USD 43.28 billion by 2030.
Electroceuticals, or bioelectric medicine, refer to a therapeutic modality that uses electrical impulses to modulate the body's neural circuits as an alternative to pharmaceuticals. This innovative approach exploits the nervous system's inherent capability to govern the body's organ functions, influencing various physiological and pathological conditions. The fundamental principle behind electroceuticals involves precisely delivering electrical signals to specific nerves, aiming to adjust their activity to treat various medical conditions. The growing elderly population, the prevalence of cardiac and neurological disorders, and the rising preference for non-invasive treatments drive the growth of the electroceuticals or bioelectric medicine market. However, the technological complexities associated with electroceuticals hinder their adoption. The ongoing innovation in bioelectric medicine, including the miniaturization of devices and improvements in battery life, and advancements in bioelectric medicine that allow for personalized treatment plans offer lucrative opportunities for the expansion of the electroceuticals or bioelectric medicine market.
Regional Insights
The Americas experiences growth in the electroceuticals/bioelectric medicine market, attributed to advanced healthcare infrastructure, strong emphasis on research and development, and high healthcare expenditure. The prevalence of chronic diseases, including cardiovascular disorders, neurological ailments, and diabetes in the Americas, fuels the need for electroceutical solutions. Additionally, partnerships between medical institutions and tech companies in the U.S. foster innovation and facilitate the development of more sophisticated and targeted electroceutical therapies. The Asia-Pacific region's electroceuticals/bioelectric medicine market is growing, driven by rapidly improving healthcare infrastructure, increasing disposable incomes, and a growing awareness of advanced medical treatments. The Asia-Pacific region's growing aging population presents a substantial patient pool for chronic diseases and significant electroceutical application areas. The EMEA region presents a diverse and evolving market for electroceuticals/bioelectric medicine, characterized by well-established healthcare systems in Europe and emerging markets in the Middle East and Africa. With its stringent regulatory framework, high healthcare standards, and a strong emphasis on research, Europe plays a crucial role in advancing the electroceutical field. The Middle East witnesses growing investments in healthcare infrastructure and an increasing inclination toward advanced medical technologies. The African region showcases the potential for growth due to rising awareness of non-pharmaceutical treatment options and efforts to improve healthcare systems.
Market Insights
Market Dynamics
The market dynamics represent an ever-changing landscape of the Electroceuticals/Bioelectric Medicine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
Market Drivers
Growing prevalence of cardiac and neurological disorders
Increasing preference for non-invasive treatments
Rising miniaturization and biocompatibility of electroceutical devices to enhance patient comfort
Market Restraints
High costs associated with electroceutical treatment
Market Opportunities
Integration of wireless technologies to improve the functionality and user experience of electroceutical devices
Rising personalization of electroceutical therapies based on individual patient profiles
Market Challenges
Technological complexities associated with the electroceuticals
Market Segmentation Analysis
Product: Increasing need for cardiac pacemakers and implantable cardioverter defibrillators owing to the prevalence of cardiovascular diseases
Application: Growing adoption of electroceuticals to manage chronic pain conditions
Market Disruption Analysis
Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Electroceuticals/Bioelectric Medicine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Electroceuticals/Bioelectric Medicine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approved Medtronic's Percept RC Deep Brain Stimulation (DBS) system
Medtronic plc secured U.S. FDA approval for its Percept RC Deep Brain Stimulation (DBS) system, marking a significant advancement in treating neurological disorders. This rechargeable neurostimulator enriches the Percept family, uniquely including sensing-enabled DBS systems such as the Percept PC neurostimulator alongside BrainSense technology and SenSight directional leads. The Percept lineup is distinct in its capability to offer personalized treatment, significantly benefiting patients with movement conditions such as Parkinson's disease, essential tremor, and dystonia, in addition to epilepsy.
Evren Technologies launched the Phoenix 100 taVNS Research System
Evren Technologies launched the Phoenix 100 system, marking a significant advancement in bioelectric medicine. This advanced research tool is designed to solve the obstacles traditionally encountered in Vagus Nerve Stimulation (VNS) studies. The Phoenix 100 transcutaneous auricular vagus nerve stimulator (taVNS) system is expected to revolutionize the landscape of VNS research by providing a compact, versatile, and advanced tool for clinical investigations.
FDA Clears Abbott's Innovative Spinal Cord Stimulation Devices for Chronic Back Pain Patients
Abbott received U.S. FDA approval for its spinal cord stimulation (SCS) devices to manage chronic back pain in individuals unable to undergo or ineligible for back surgery. This approval is grounded in the findings from the DISTINCT study, which showcased the efficacy of Abbott's BurstDR SCS technology in enhancing pain relief, daily function, and emotional well-being in individuals suffering from chronic back pain.
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Electroceuticals/Bioelectric Medicine Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Electroceuticals/Bioelectric Medicine Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aleva Neurotherapeutics SA, Bioinduction Ltd., BIOTRONIK SE & Co. KG, BioWave Corporation, Boston Scientific Corporation, CEFALY Technology sprl, Cochlear Limited, electroCore, Inc., Galvani Bioelectronics by GSK PLC, Gimer Medical Co., Ltd., LivaNova PLC, MED-EL Elektromedizinische Geräte GmbH, Medtronic PLC, NeuroPace, Inc., Nevro Corp., Oticon Medical, Second Sight Medical Products, Inc., and Sonova Holding AG.
Market Segmentation & Coverage
This research report categorizes the Electroceuticals/Bioelectric Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:
Product
Cardiac Pacemakers & Implantable Cardioverter Defibrillators
Cochlear Implants
Deep Brain Stimulators
Retinal Implants
Spinal Cord Stimulators
Vagus Nerve Stimulators
Device
Implantable Electroceutical Devices
Noninvasive Electroceutical Devices
Application
Arrhythmia
Chronic Pain
Epilepsy
Parkinson’s Disease
Retinitis Pigmentosa
Sensorineural Hearing Loss
End-User
Ambulatory Centers
Home Care Settings
Hospitals & Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
192 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing prevalence of cardiac and neurological disorders
- 5.1.1.2. Increasing preference for non-invasive treatments
- 5.1.1.3. Rising miniaturization and biocompatibility of electroceutical devices to enhance patient comfort
- 5.1.2. Restraints
- 5.1.2.1. High costs associated with electroceutical treatment
- 5.1.3. Opportunities
- 5.1.3.1. Integration of wireless technologies to improve the functionality and user experience of electroceutical devices
- 5.1.3.2. Rising personalization of electroceutical therapies based on individual patient profiles
- 5.1.4. Challenges
- 5.1.4.1. Technological complexities associated with the electroceuticals
- 5.2. Market Segmentation Analysis
- 5.2.1. Product: Increasing need for cardiac pacemakers and implantable cardioverter defibrillators owing to the prevalence of cardiovascular diseases
- 5.2.2. Application: Growing adoption of electroceuticals to manage chronic pain conditions
- 5.3. Market Disruption Analysis
- 5.4. Porter’s Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
- 5.5. Value Chain & Critical Path Analysis
- 5.6. Pricing Analysis
- 5.7. Technology Analysis
- 5.8. Patent Analysis
- 5.9. Trade Analysis
- 5.10. Regulatory Framework Analysis
- 6. Electroceuticals/Bioelectric Medicine Market, by Product
- 6.1. Introduction
- 6.2. Cardiac Pacemakers & Implantable Cardioverter Defibrillators
- 6.3. Cochlear Implants
- 6.4. Deep Brain Stimulators
- 6.5. Retinal Implants
- 6.6. Spinal Cord Stimulators
- 6.7. Vagus Nerve Stimulators
- 7. Electroceuticals/Bioelectric Medicine Market, by Device
- 7.1. Introduction
- 7.2. Implantable Electroceutical Devices
- 7.3. Noninvasive Electroceutical Devices
- 8. Electroceuticals/Bioelectric Medicine Market, by Application
- 8.1. Introduction
- 8.2. Arrhythmia
- 8.3. Chronic Pain
- 8.4. Epilepsy
- 8.5. Parkinson’s Disease
- 8.6. Retinitis Pigmentosa
- 8.7. Sensorineural Hearing Loss
- 9. Electroceuticals/Bioelectric Medicine Market, by End-User
- 9.1. Introduction
- 9.2. Ambulatory Centers
- 9.3. Home Care Settings
- 9.4. Hospitals & Clinics
- 10. Americas Electroceuticals/Bioelectric Medicine Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Electroceuticals/Bioelectric Medicine Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Electroceuticals/Bioelectric Medicine Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. FDA Approved Medtronic's Percept RC Deep Brain Stimulation (DBS) system
- 13.3.2. Evren Technologies launched the Phoenix 100 taVNS Research System
- 13.3.3. FDA Clears Abbott's Innovative Spinal Cord Stimulation Devices for Chronic Back Pain Patients
- 13.4. Strategy Analysis & Recommendation
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.